Filing Flows › Arbutus Biopharma (ABUS) › Q4 2025
Arbutus Biopharma (ABUS) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 23, 2026
Arbutus Biopharma (ABUS) reported revenue of $1.1M for the fourth quarter 2025 (Q4 2025), -33% from a year earlier and +99% from the quarter before. Operating margin was -503.3%, net loss $3.8M (357.4% of revenue).
Arbutus Biopharma, Q4 2025: revenue $1.1M (-33% year over year), operating margin -503.3%, net loss $3.8M, operating cash flow −$4.7M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.1M | +99% | -33% |
| Operating profit | −$5.3M | — | — |
| Net earnings | −$3.8M | — | — |
| Operating cash flow | −$4.7M | — | — |
What changed
Revenue was $1.1M in Q4 2025, down 33% year over year and up 99% from the previous quarter. Collaborations and licenses was the largest line at 75% of revenue.
Operating costs exceeded revenue by $5.3M, an operating margin of -503.3%. Total costs fell 59% while revenue fell 33%. The quarter ended with a net loss of $3.8M, narrower than the previous quarter's $7.7M loss. Non-operating items added $1.5M, -41% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$4.7M. Non-cash charges added back $11K of depreciation and amortization and $1.3M of share-based compensation. Working capital and other items used $2.2M.
Questions
What was Arbutus Biopharma's revenue in the fourth quarter 2025?
Arbutus Biopharma (ABUS) reported revenue of $1.1M for the fourth quarter 2025 (Q4 2025), -33% from a year earlier and +99% from the quarter before.
Was Arbutus Biopharma profitable in the fourth quarter 2025?
Operating loss was $5.3M (-503.3% of revenue) and net loss $3.8M.
Source: Arbutus Biopharma 10-K on SEC EDGAR.